UK Plasmid Dna Contract Manufacturing Market Size & Outlook

The plasmid dna contract manufacturing market in UK is expected to reach a projected revenue of US$ 56.9 million by 2030. A compound annual growth rate of 20% is expected of UK plasmid dna contract manufacturing market from 2024 to 2030.
Revenue, 2023 (US$M)
$15.9
Forecast, 2030 (US$M)
$56.9
CAGR, 2024 - 2030
20%
Report Coverage
UK

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

UK plasmid dna contract manufacturing market, 2018-2030 (US$M)

UK plasmid dna contract manufacturing market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

UK plasmid dna contract manufacturing market highlights

  • The UK plasmid dna contract manufacturing market generated a revenue of USD 15.9 million in 2023 and is expected to reach USD 56.9 million by 2030.
  • The UK market is expected to grow at a CAGR of 20% from 2024 to 2030.
  • In terms of segment, cell & gene therapy was the largest revenue generating application in 2023.
  • Cell & Gene Therapy is the most lucrative application segment registering the fastest growth during the forecast period.


Plasmid dna contract manufacturing market data book summary

Market revenue in 2023USD 15.9 million
Market revenue in 2030USD 56.9 million
Growth rate20% (CAGR from 2023 to 2030)
Largest segmentCell & gene therapy
Fastest growing segmentCell & Gene Therapy
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationCell & Gene Therapy, Immunotherapy
Key market players worldwideCharles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster


Other key industry trends

  • In terms of revenue, UK accounted for 4.9% of the global plasmid dna contract manufacturing market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, UK plasmid dna contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 56.9 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Plasmid DNA Contract Manufacturing Market Companies

Name Profile # Employees HQ Website
Esco Aster View profile 11-50 Singapore, Central Region, Singapore, Asia https://escoaster.com
PlasmidFactory View profile 11-50 Bielefeld, Nordrhein-Westfalen, Germany, Europe https://plasmidfactory.com/
VGXI View profile 101-250 The Woodlands, Texas, United States, North America https://vgxii.com/
Viva Biotech View profile 1001-5000 Shanghai, Shanghai, China, Asia http://www.vivabiotech.com.cn/
BioCina View profile 101-250 Thebarton, South Australia, Australia, Oceania https://www.biocina.com/
TriLink BioTechnologies View profile 251-500 San Diego, California, United States, North America http://www.trilinkbiotech.com/
Boehringer Ingelheim View profile 10001+ Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe https://www.boehringer-ingelheim.com/
Charles River Laboratories International Inc View profile 21400 251 Ballardvale Street, Wilmington, MA, United States, 01887 https://www.criver.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com
Lonza Group Ltd View profile 18000 Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 https://www.lonza.com

UK plasmid dna contract manufacturing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.


Cell & gene therapy was the largest segment with a revenue share of 60.38% in 2023. Horizon Databook has segmented the UK plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.


The increasing geriatric population and growing prevalence of chronic diseases, such as chronic liver disease, diabetes, infectious diseases, genetic diseases, cardiovascular diseases, & cancer, are the primary factors contributing to market growth.

Presence of a large number of players and the strategic initiatives undertaken by them, such as acquisitions & expansion of therapeutic options, would increase contract manufacturing of pDNA and would also fulfill the requirements of pharmaceutical & biotech companies in terms of quality standards and manufacturing with help of the contract manufacturing firms.

Reasons to subscribe to UK plasmid dna contract manufacturing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of UK plasmid dna contract manufacturing market databook

  • Our clientele includes a mix of plasmid dna contract manufacturing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the UK plasmid dna contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into UK plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

UK plasmid dna contract manufacturing market size, by therapeutic area, 2018-2030 (US$M)

UK Plasmid DNA Contract Manufacturing Market Outlook Share, 2023 & 2030 (US$M)

UK plasmid dna contract manufacturing market size, by therapeutic area, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online